---
title: 'Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction
  and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI
  trial'
date: '2024-10-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39432252/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241021184321&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'Cardiogenic shock (CS) is a devastating and fatal complication of acute
  myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics
  of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor
  for CS-AMI, in terms of both efficacy and safety. The DAPT-SHOCK-AMI trial (ClinicalTrials.gov:
  NCT03551964; EudraCT: 2018-002161-19) will assess the benefits of cangrelor in patients
  with an initial CS-AMI undergoing primary angioplasty. This ...'
disable_comments: true
---
Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety. The DAPT-SHOCK-AMI trial (ClinicalTrials.gov: NCT03551964; EudraCT: 2018-002161-19) will assess the benefits of cangrelor in patients with an initial CS-AMI undergoing primary angioplasty. This ...